SCHEMBL880317

SCHEMBL880317

O=C1CC(c2cccc(Cl)c2)c2ccc3ccccc3c21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
EEF2K O00418 1/20 0.42
TP53 P04637 2/20 0.41
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
HTR2B P41595 4/20 0.40
HRH3 Q9Y5N1 4/20 0.40
CYP19A1 P11511 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10280646 0.86 EEF2K (0.44) LMNAALDH1A1KDM4EMAPK1SMN1; SMN2
SCHEMBL880279 0.79 TP53 (0.46) LMNAALDH1A1KDM4EMAPK1SMN1; SMN2
SCHEMBL880286 0.78 MAPT (0.56) LMNAALDH1A1KDM4EMAPK1SMN1; SMN2
SCHEMBL880435 0.78 MAPT (0.68) LMNAALDH1A1MAPK1SMN1; SMN2KMT2A
SCHEMBL14047508 0.78 EEF2K (0.44) LMNAALDH1A1KDM4EMAPK1SMN1; SMN2
SCHEMBL12162752 0.78 CYP19A1 (0.49) LMNAALDH1A1KDM4EMAPK1KMT2A
SCHEMBL12162742 0.73 IDO1 (0.42) LMNAALDH1A1KDM4EMAPK1KMT2A
SCHEMBL880433 0.73 TP53 (0.69) LMNAALDH1A1SMN1; SMN2KMT2AMAPT
SCHEMBL12278879 0.73 ALDH1A1 (0.46) LMNAALDH1A1KDM4EMAPK1MAPT
SCHEMBL880302 0.71 LMNA (0.65) LMNAALDH1A1MAPK1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT LMNA 525/4885ALDH1A1 171/4885KDM4E 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.